Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401354 | 0.83 | ALDH1A1 (0.39) | DGAT1NPC1 | |
| SCHEMBL3496820 | 0.81 | DGAT1 (0.35) | DGAT1NPC1 | |
| SCHEMBL20745963 | 0.81 | DGAT1 (0.31) | DGAT1NPC1 | |
| SCHEMBL30789772 | 0.80 | DGAT1 (0.33) | DGAT1NPC1 | |
| SCHEMBL20744490 | 0.80 | DGAT1 (0.40) | DGAT1NPC1 | |
| SCHEMBL31308722 | 0.80 | DGAT1 (0.35) | DGAT1NPC1 | |
| SCHEMBL23791796 | 0.79 | — | — | |
| SCHEMBL5246866 | 0.79 | NPC1 (0.33) | DGAT1NPC1 | |
| SCHEMBL31741697 | 0.79 | DGAT1 (0.32) | DGAT1NPC1 | |
| SCHEMBL17110040 | 0.79 | DGAT1 (0.34) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4543882-A1 | MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | REPARE THERAPEUTICS INC. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20250026750-A1 | SULFOXIMINE-CONTAINING ATR INHIBITOR COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024171094-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-08-22 | — | — | WO | disclosed |
| CN-114174292-A | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors | 修复治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-113454080-A | Compounds, pharmaceutical compositions and methods of making compounds and methods of use thereof | 修复治疗公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
| CN-110627796-A | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-106795138-A | New EEDQ pyrazolyl compounds | 豪夫迈·罗氏有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106604917-A | Novel dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors | 豪夫迈·罗氏有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-101018780-B | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | PFIZER | 2012-01-11 | — | — | CN | disclosed |
| EP-1784396-B1 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-12-22 | — | — | EP | disclosed |
| CN-101018780-A | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMA (US) | 2007-08-15 | — | — | CN | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | DGAT1 4258/4885NPC1 3013/4885 |
| US-20250026750-A1 | SULFOXIMINE-CONTAINING ATR INHIBITOR COMPOUND | ATR, ATRIP, FANCF | DGAT1 3677/4885NPC1 4685/4885 |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | DGAT1 3781/4885NPC1 1796/4885 |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | DGAT1 2336/4885NPC1 219/4885 |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | ATR, CHEK2, CHEK1 | DGAT1 3781/4885NPC1 1796/4885 |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | DGAT1 3781/4885NPC1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.